Discovery and evaluation of N-(triazin-1,3,5-yl) phenylalanine derivatives as VLA-4 integrin antagonists

被引：24

作者：

Porter, JR ^{[1
]}

Archibald, SC ^{[1
]}

Brown, JA ^{[1
]}

Childs, K ^{[1
]}

Critchley, D ^{[1
]}

Head, JC ^{[1
]}

Hutchinson, B ^{[1
]}

Parton, TAH ^{[1
]}

Robinson, MK ^{[1
]}

Shock, A ^{[1
]}

Warrellow, GJ ^{[1
]}

Zomaya, A ^{[1
]}

机构：

[1] Celltech R&D Ltd, Slough SL1 4EN, Berks, England

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2002年 / 12卷 / 12期

关键词：

D O I：

10.1016/S0960-894X(02)00237-8

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

SAR studies aimed at improving the rate of clearance of a series of VLA-4 integrin antagonists by the introduction of a 1,3,5-triazine as an amide isostere are described. (C) 2002 Elsevier Science Ltd. All rights reserved.

引用

页码：1591 / 1594

页数：4

共 6 条

[1] Discovery and evaluation of potent, tyrosine-based α4β1 integrin antagonists [J].

Archibald, SC ;

Head, JC ;

Gozzard, N ;

Howat, DW ;

Parton, TAH ;

Porter, JR ;

Robinson, MK ;

Shock, A ;

Warrellow, GJ ;

Abraham, WM .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2000, 10 (09) :997-999

[2]

ELICES M, 1999, CURR OPIN ANTIINFLAM, V1, P14

[3]

ELICES MJ, 1998, CELL ADHESION MOL MA, P133

[4]

FRINK EJ, 1990, ANESTH ANALG, V71, P484

[5]

Porter J R, 2000, IDrugs, V3, P788

[6] Natalizumab. Treatment of IBD, Treatment of multiple sclerosis [J].

Sorbera, LA ;

Martin, L ;

Rabasseda, X .

DRUGS OF THE FUTURE, 2000, 25 (09) :917-921

← 1 →